Hormone receptor positive HER2 negative breast cancer
Not recruitingStudy Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:CapecitabineEribulin Mesylate+3
Germany- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:AstraZeneca AB










